The Relationship among Pore-Size Ratings, Bubble Points, and Porosity - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

The Relationship among Pore-Size Ratings, Bubble Points, and Porosity

Pharmaceutical Technology

35. EMEA CPMP/QMP/489/95, Note For Guidance in Manufacture of the Finished Dosage Form, 5-6 (April reissue 1996).

36. J.P. Agalloco, "Guest Editorial: It Just Doesn't Matter," PDA J. Pharm. Sci. Technol. 52 (4), 149–150 (1998).

37. Society of Automotive Engineers (SAE), Bubble Point Test. Method, Aerospace Recommended Practice ARP-901 (1968).

38. M.W. Jornitz and T.H. Meltzer, Filtration Handbook: Integrity Testing (PDA, Bethesda, MD; DHI Publishing, River Grove, IL, 2003).

39. D.B. Pall, "Quality Control of Absolute Bacteria Removal Filters," Bull. PDA 29, 192–212 (1975).

40. A. Baszkin, D.J. Lyman, and T.H. Meltzer, "Theoretical Considerations of BubblePoint Measurement: Solid/Liquid Wetting Interaction," Pharm. Technol. Int. 2 (l), 22–31 (1978).

41. P.R. Johnston and T.H. Meltzer, "Comments on Organism Challenge Levels in Sterilizing-Filter Efficiency Testing," Pharm. Technol. 3 (11), 66–70, 110 (1979).

42. W.J. Elford, "The Principles of Ultrafiltration as Applied in Biological Studies," Proceedings of the Royal Society, 112B (London, UK, 1933), pp. 384–406.

43. A.R. Reti, "An Assessment of Test Criteria in Evaluating the Performance and Integrity of Sterilizing Filters," Bull. Paren Drug Assoc. 3l (4), 187–194 (1977).

44. D.C. Grant and J.G. Zahke, "Sieving Capture of Particles by MicroporousMembrane Filters From Clean Liquids," Swiss Contamin. Control 3 (4a), 160–164 (1990).

45. M.L. Roberts and D.J. Valazquez, "Characterizing the Rating and Performance of Membrane Filter for Liquid Applications Using Latex Spheres," Swiss Contam. Quarterly 3, 71–74 (1990).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here